(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
Live Chart Being Loaded With Signals
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States...
Stats | |
---|---|
今日成交量 | 13 126.00 |
平均成交量 | 18 037.00 |
市值 | 37.57M |
EPS | $0 ( 2024-03-27 ) |
下一个收益日期 | ( $0 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.65 |
ATR14 | $0.101 (2.39%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-06-30 | Lurier Eliot M | Buy | 0 | |
2021-03-16 | Eansor Norman David | Buy | 14 285 | Common Stock |
2023-06-06 | Eansor Norman David | Buy | 8 000 | Stock Option (right to buy) |
2021-03-25 | Eansor Norman David | Buy | 7 142 | Common Stock |
2021-03-25 | Eansor Norman David | Sell | 14 285 | Common Stock |
INSIDER POWER |
---|
100.00 |
Last 91 transactions |
Buy: 66 397 235 | Sell: 1 245 536 |
Marker Therapeutics Inc 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Marker Therapeutics Inc 财务报表
Annual | 2023 |
营收: | $3.31M |
毛利润: | $-7.11M (-214.60 %) |
EPS: | $-1.930 |
FY | 2023 |
营收: | $3.31M |
毛利润: | $-7.11M (-214.60 %) |
EPS: | $-1.930 |
FY | 2022 |
营收: | $9.00M |
毛利润: | $5.32M (59.13 %) |
EPS: | $-3.58 |
FY | 2021 |
营收: | $1 242.00 |
毛利润: | $1 241.71 (100.00 %) |
EPS: | $-8.90 |
Financial Reports:
No articles found.
Marker Therapeutics Inc
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。